The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects
Open accessAbstract
Summary: Background: Using a monoclonal antibody with greater affinity for IgE than omalizumab, we examined whether more complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin prick responses to allergen. Objective: To explore the pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity humanized monoclonal IgG1κ anti‐IgE. Methods: Preclinical assessments and two randomized, placebo‐controlled, double‐blind clinical trials were conducted in atopic subjects. The first trial administered single doses of QGE 031 (0.1–10 mg/kg) or placebo intravenously, while the second trial administered two to four doses of QGE 031 (0.2– 4 mg/kg) or placebo subcutaneously at 2‐week intervals. Both trials included an open‐label omalizumab arm. Results: Sixty of 73 (82%) and 96 of 110 (87%) subjects completed the intravenous and subcutaneous studies, respectively. Exposure to QGE 031 and its half‐life depended on the QGE 031 dose and serum IgE level. QGE 031 had a biexponential pharmacokinetic profile after intravenous administration and a terminal half‐life of approximately 20 days. QGE 031 demonstrated dose‐ and time‐dependent suppression of free IgE, basophil Fcε RI and basophil surface IgE superior in extent (free IgE and surface IgE) and duration to omalizumab. At Day 85, 6 weeks after the last dose, skin prick wheal responses to allergen were suppressed by > 95% and 41% in subjects treated subcutaneously with QGE 031 (2 mg/kg) or omalizumab, respectively (P < 0.001). Urticaria was observed in QGE 031‐ and placebo‐treated subjects and was accompanied by systemic symptoms in one subject treated with 10 mg/kg intravenous QGE 031. There were no serious adverse events. Conclusion and Clinical Relevance: These first clinical data for QGE 031, a high‐affinity IgG1κ anti‐IgE, demonstrate that increased suppression of free IgE compared with omalizumab translated to superior pharmacodynamic effects in atopic subjects, including those with high IgE levels. QGE 031 may therefore benefit patients unable to receive, or suboptimally treated with, omalizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799
Cited by
The role of allergen‐specific IgE, IgG and IgA in allergic disease
Shamji, M. H., Valenta, R., Jardetzky, T., Verhasselt, V., Durham, S. R., Würtzen, P. A., & van Neerven, R. J. J. (2021) · Allergy · doi:10.1111/all.14908 · Cited by 336
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
Bachert, C., Zhang, L., & Gevaert, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.010 · Cited by 317
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017) · Allergy · doi:10.1111/all.13083 · Cited by 293
Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0044-7 · Cited by 187
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Metadata
- Authors
- Arm, J. P., Bottoli, I., Skerjanec, A., Floch, D., Groenewegen, A., Maahs, S., Owen, C. E., Jones, I., & Lowe, P. J.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2014-10-21
- Volume
- 44
- Issue
- 11
- Pages
- 1371-1385
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2102629488
- Cited by
- 248
- References
- 1
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.